We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Protein Expression in Human Neuroblastoma Tumor Samples

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01407731
First Posted: August 2, 2011
Last Update Posted: May 17, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
  Purpose

RATIONALE: Studying protein expression in samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat neuroblastoma.

PURPOSE: This laboratory studying is looking at protein expression in tumor tissue samples from patients with neuroblastoma.


Condition Intervention
Neuroblastoma Genetic: protein expression analysis Genetic: western blotting Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Analysis of Intersectin Expression in Primary Human Neuroblastomas

Resource links provided by NLM:


Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • ITSN1 is highly expressed in neuroblastoma tumors and plays an important role in the development/progression of these tumors

Enrollment: 20
Study Start Date: July 2011
Study Completion Date: May 2016
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To determine whether intersectin (ITSN1) proteins are present at elevated levels in primary human tumor samples.

OUTLINE: Archived tumor tissue samples are analyzed for intersectin (ITSN1) expression by western blot assays with enhanced chemiluminescence and exposed to X-ray film. The films are scanned, and levels of ITSN1 signal are quantified by densitometry.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosed with neuroblastoma.
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosed with neuroblastoma
  • Banked primary tumor samples from patients with stage 1, 2, 3, and 4 disease

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01407731


Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Principal Investigator: John P. O'Bryan, PhD University of Illinois at Chicago
  More Information

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT01407731     History of Changes
Other Study ID Numbers: ANBL11B4
COG-ANBL11B4 ( Other Identifier: Children's Oncology Group )
ANBL11B4 ( Other Identifier: Children's Oncology Group )
NCI-2011-03799 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Submitted: July 30, 2011
First Posted: August 2, 2011
Last Update Posted: May 17, 2016
Last Verified: May 2016

Keywords provided by Children's Oncology Group:
disseminated neuroblastoma
localized resectable neuroblastoma
localized unresectable neuroblastoma
stage 4S neuroblastoma

Additional relevant MeSH terms:
Neuroblastoma
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue